Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metamucil Capsule Convenience Ad Claims Upheld By NAD

This article was originally published in The Tan Sheet

Executive Summary

Advertising claims that Procter & Gamble's Metamucil fiber capsules are a convenient alternative to the brand's powder form are substantiated, the National Advertising Division of the Council of Better Business Bureaus concluded in a recent inquiry

You may also be interested in...



Metamucil capsules

P&G ads for latest extension of laxative powders, wafers brand will focus on convenience, portability, firm says. TV, radio, print ad campaign designed by D'Arcy Masius Benton & Bowles (New York) will launch once capsules reach 50% distribution. Product began reaching shelves Sept. 30, with full distribution expected by mid-December. Capsules are sold in 100-, 160-count bottles with SRP of $7.99-$9.99 and $9.99-$12.99, respectively. Each dose of two to six capsules contains roughly 3.4 g of psyllium husk (2.4 g soluble fiber); consumers are advised to take up to three doses per day with 8 oz. of water. Metamucil's dual benefit as fiber supplement that may carry FDA-approved heart disease risk-reduction health claim could help propel line extension to top of the branded laxatives tablet category, which is now led by Novartis' Dulcolax, Ex-Lax, according to IRI data...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel